Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disease & Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FTO epitranscriptomic drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FTO Catalytic Domain (WT & Mutant) Recombinant Protein High purity (>95%), Endotoxin <1EU/ug, Sequence Verified, Theoretical MW confirmed. |
View FTO Products |
| Gene Delivery | FTO Lentivirus Particles Full-length ORF for stable cell line construction. HEK293 expressed. |
View FTO Products |
| Benchmark Ab | Anti-FTO Monoclonal Antibody Recombinant positive control for Western/IP applications. |
View FTO Products |
| Validator | FTO siRNA Set (3 unique sequences) For knockdown verification and specificity controls. |
View FTO Products |
| Paralog Control | ALKBH5 Recombinant Protein Selectivity counter-screening (m6A demethylase family). |
View ALKBH5 Products |
| Pathway Partner | METTL3 Recombinant Protein Methyltransferase counterpoint for epitranscriptomic balance studies. |
View METTL3 Products |
| Reader Protein | YTHDF2 Recombinant Protein m6A reader domain for binding competition assays. |
View YTHDF2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Paralog Selectivity (vs ALKBH5) | Human FTO & ALKBH5 proteins purified in parallel with >95% purity; Sequence-verified catalytic domains for orthogonal screening |
| Enzymatic Activity Standardization | High-purity FTO with confirmed theoretical MW; suitable for Alpha-KG consumption and LC-MS/MS demethylation assays |
| Cellular Permeability Validation | Lentivirus packaging for stable FTO-overexpressing cell lines; ideal for CETSA and target engagement studies |
| False Positive Controls | siRNA set included for specificity verification in cellular demethylation assays |
Live FTO R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FTO therapeutics is intensifying, with major players shifting focus from traditional metabolic targets to epitranscriptomic modulation. As an m6A RNA demethylase, FTO overexpression is tightly linked to leukemia (AML) and solid tumors. As first-generation inhibitors (FB23-2, CS1) advance toward clinic, the next wave of R&D is targeting combination therapies with METTL3 inhibitors and immune checkpoint blockade, alongside the critical need for paralog-selective compounds that spare ALKBH5. Selective PROTAC degraders and brain-penetrant analogs for glioblastoma are also emerging as promising modalities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | China Pharmaceutical Univ (FB23-2), Univ of Chicago (CS1) | AML, Solid Tumors | Enzymatic Assay (Need high-purity catalytic domain protein) |
| Protein Degraders (PROTAC) | Various Biotechs | AML, GBM | Cell Line Construction (Need Lentivirus for stable FTO expression) |
| Metabolic Disease Agents | Pharmaceutical Industry | Obesity, T2D | Paralog Selectivity (Need ALKBH5/FTO dual panel) |
| Allosteric Modulator | Early discovery biotechs | Metabolic disease, Oncology | Conformational binding assay (Need WT vs mutant full-length protein) |